Search

Your search keyword '"Cauda, R (ORCID:0000-0002-1498-4229)"' showing total 5 results
Start Over Author "Cauda, R (ORCID:0000-0002-1498-4229)" Publisher john wiley and sons inc
5 results on '"Cauda, R (ORCID:0000-0002-1498-4229)"'

1. The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immuno-escaping ability

Author

Pascarella, S., Bianchi, M., Giovanetti, M., Narzi, D., Cauda, Roberto, Cassone, A., Ciccozzi, M., Cauda R. (ORCID:0000-0002-1498-4229), Pascarella, S., Bianchi, M., Giovanetti, M., Narzi, D., Cauda, Roberto, Cassone, A., Ciccozzi, M., and Cauda R. (ORCID:0000-0002-1498-4229)

Abstract

The COVID-19 pandemic continues to have a threatening impact on a global scale, largely due to the emergence of newly SARS-CoV-2 variants. The Mu (PANGO lineage B.1.621), was first identified in Colombia in January 2021 and was classified as a variant of interest (VOI) in August 2021, due to a constellation of mutations that likely-mediate an unexpectedly enhanced immune resistance to inactivated vaccine-elicited antibodies. Despite recent studies suggesting that the Mu variant appears to have less infectivity than the Delta variant, here we examined the structural effect of the Mu spike protein mutations and predicted the potential impact on infectivity of the Mu variant compared with the Delta and Delta plus spike protein.

Published
2022

3. Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project

Author

Ponziani, Francesca Romana, Santopaolo, Francesco, Siciliano, Massimo, De Belvis, A. G., Tortora, Annalisa, Mora, Vincenzina, Fanali, Chiara, Morsella, Alisha, Balducci, Federica, Vetrugno, Giuseppe, D'Alfonso, Maria Elena, Cambieri, Andrea, Cauda, Roberto, Bellantone, Rocco Domenico Alfonso, Sanguinetti, Maurizio, Pompili, Maurizio, Gasbarrini, Antonio, Ponziani F. R. (ORCID:0000-0002-5924-6238), Santopaolo F., Siciliano M., Tortora A., Mora V., Fanali C., Morsella A., Balducci F., Vetrugno G. (ORCID:0000-0003-0181-2855), D'Alfonso M. E., Cambieri A., Cauda R. (ORCID:0000-0002-1498-4229), Bellantone R. (ORCID:0000-0002-0844-3469), Sanguinetti M. (ORCID:0000-0002-9780-7059), Pompili M. (ORCID:0000-0001-6699-7980), Gasbarrini A. (ORCID:0000-0002-7278-4823), Ponziani, Francesca Romana, Santopaolo, Francesco, Siciliano, Massimo, De Belvis, A. G., Tortora, Annalisa, Mora, Vincenzina, Fanali, Chiara, Morsella, Alisha, Balducci, Federica, Vetrugno, Giuseppe, D'Alfonso, Maria Elena, Cambieri, Andrea, Cauda, Roberto, Bellantone, Rocco Domenico Alfonso, Sanguinetti, Maurizio, Pompili, Maurizio, Gasbarrini, Antonio, Ponziani F. R. (ORCID:0000-0002-5924-6238), Santopaolo F., Siciliano M., Tortora A., Mora V., Fanali C., Morsella A., Balducci F., Vetrugno G. (ORCID:0000-0003-0181-2855), D'Alfonso M. E., Cambieri A., Cauda R. (ORCID:0000-0002-1498-4229), Bellantone R. (ORCID:0000-0002-0844-3469), Sanguinetti M. (ORCID:0000-0002-9780-7059), Pompili M. (ORCID:0000-0001-6699-7980), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Italy is one of the countries on track with the WHO’s agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named ‘Telepass’ project, for patients exposed to HCV infection who have not yet been linked to care in a large tertiary care centre. The ‘Telepass’ project was structured in two phases: (a) a retrospective analysis first identified all anti–HCV-positive subjects among patients who underwent pre-operative assessment in the facility in the course of one year; (b) a following prospective phase, aimed to recall patients in need either of further diagnostic tests (ie HCV-RNA) or treatment. A total of 12246 records of patients tested for HCV antibodies were reviewed. The overall prevalence of anti–HCV-positive subjects was 1.83% (224/12246) with a male/female ratio of 2.07. Out of the 224 anti–HCV-positive patients, 123 (54.91%) did not have documented HCV-RNA tests and were therefore selected for recall. Of these, 123 were reachable and 26 (21.13%) were successfully linked to care. Ten patients (38.46%) tested HCV-RNA positive and initiated treatment with direct-acting antivirals (DAAs). The Telepass study highlights that a recall strategy starting from internal hospital databases can help identify patients with chronic HCV infection who have not yet been linked to care, and provides an epidemiological insight into the prevalence of HCV infection in Italy in the late DAAs era.

Published
2021

4. Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission

Author

Benvenuto, D., Demir, A. B., Giovanetti, M., Bianchi, M., Angeletti, S., Pascarella, S., Cauda, Roberto, Ciccozzi, M., Cassone, A., Cauda R. (ORCID:0000-0002-1498-4229), Benvenuto, D., Demir, A. B., Giovanetti, M., Bianchi, M., Angeletti, S., Pascarella, S., Cauda, Roberto, Ciccozzi, M., Cassone, A., and Cauda R. (ORCID:0000-0002-1498-4229)

Abstract

Italy is the first western country suffering heavy severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and disease impact after coronavirus disease-2019 pandemia started in China. Even though the presence of mutations on spike glycoprotein and nucleocapsid in Italian isolates has been reported, the potential impact of these mutations on viral transmission has not been evaluated. We have compared SARS-CoV-2 genome sequences from Italian patients with virus sequences from Chinese patients. We focussed upon three nonsynonymous mutations of genes coding for S(one) and N (two) viral proteins present in Italian isolates and absent in Chinese ones, using various bioinformatics tools. Amino acid analysis and changes in three-dimensional protein structure suggests the mutations reduce protein stability and, particularly for S1 mutation, the enhanced torsional ability of the molecule could favor virus binding to cell receptor(s). This theoretical interpretation awaits experimental and clinical confirmation.

Published
2020

5. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

Author

Mondi, A., Cozzi-Lepri, A., Tavelli, A., Rusconi, S., Vichi, F., Ceccherini-Silberstein, F., Calcagno, A., De Luca, A., Maggiolo, F., Marchetti, G., Antinori, A., d'Arminio Monforte, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, Giuseppe, Azzarin, A., Rezza, Giovanni, von Schloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Perno, C. F., Balotta, C., Bandera, A., Bonora, S., Borderi, M., Capetti, A., Capobianchi, M. R., Cicalini, S., Cingolani, Antonella, Cinque, P., Di Biagio, Anna, Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Aracino, A., Sarmati, L., Fanti, I., Lorenzini, P., Rodano', A., Macchia, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, I. A., Costantini, A., Barocci, V., Angarano, G., Fabrizio, C., Suardi, C., I, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Cacopardo, Beatrice Marina, Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Cassola, G., Viscoli, C., Lessandrini, A., Bobbio, N., Mazzarello, G., Pozzetto, I., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Bai, F., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Cristaudo, A., Vullo, V., Acinapura, R., Baldin, G., Capozzi, M., Rivano Capparucia, M., Iaiani, G., Atini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Ondero, A., Pellizzer, G., Manfrin, V., Starnini, G., Alungo, A., Cauda R. (ORCID:0000-0002-1498-4229), Ippolito G., Rezza G., Cingolani A. (ORCID:0000-0002-3793-2755), Di Biagio A., Cacopardo B., Rossetti B., Mondi, A., Cozzi-Lepri, A., Tavelli, A., Rusconi, S., Vichi, F., Ceccherini-Silberstein, F., Calcagno, A., De Luca, A., Maggiolo, F., Marchetti, G., Antinori, A., d'Arminio Monforte, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, Giuseppe, Azzarin, A., Rezza, Giovanni, von Schloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Perno, C. F., Balotta, C., Bandera, A., Bonora, S., Borderi, M., Capetti, A., Capobianchi, M. R., Cicalini, S., Cingolani, Antonella, Cinque, P., Di Biagio, Anna, Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Aracino, A., Sarmati, L., Fanti, I., Lorenzini, P., Rodano', A., Macchia, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, I. A., Costantini, A., Barocci, V., Angarano, G., Fabrizio, C., Suardi, C., I, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Cacopardo, Beatrice Marina, Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Cassola, G., Viscoli, C., Lessandrini, A., Bobbio, N., Mazzarello, G., Pozzetto, I., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Bai, F., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Cristaudo, A., Vullo, V., Acinapura, R., Baldin, G., Capozzi, M., Rivano Capparucia, M., Iaiani, G., Atini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Ondero, A., Pellizzer, G., Manfrin, V., Starnini, G., Alungo, A., Cauda R. (ORCID:0000-0002-1498-4229), Ippolito G., Rezza G., Cingolani A. (ORCID:0000-0002-3793-2755), Di Biagio A., Cacopardo B., and Rossetti B.

Abstract

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virological failure using Kaplan–Meier curves. We used Cox regression model to investigate predictors of DTG discontinuation. Results: About 1679 individuals (932 ART-naïve, 747 TE) were included. The one- and two-year probabilities (95% CI) of DTG discontinuation were 6.7% (4.9 to 8.4) and 11.5% (8.7 to 14.3) for ART-naïve and 6.6% (4.6 to 8.6) and 7.6% (5.4 to 9.8) for TE subjects. In both ART-naïve and TE patients, discontinuations of DTG were mainly driven by toxicity with an estimated risk (95% CI) of 4.0% (2.6 to 5.4) and 2.5% (1.3 to 3.6) by one year and 5.6% (3.8 to 7.5) and 4.0% (2.4 to 5.6) by two years respectively. Neuropsychiatric events were the main reason for stopping DTG in both ART-naïve (2.1%) and TE (1.7%) patients. In ART-naïve, a concomitant AIDS diagnosis predicted the risk of discontinuing DTG for any reason (adjusted relative hazard (aRH) = 3.38, p = 0.001), whereas starting DTG in combination with abacavir (ABC) was associated with a higher risk of discontinuing because of toxicity (aRH = 3.30, p = 0.009). TE patients starting a DTG-based dual therapy compared to a triple therapy had a lower risk of discontinuation for any reason (adjusted hazard ratio (aHR) = 2.50, p = 0.037 for ABC-based triple-th

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results